Whalesbook
कंपनी के सालाना नतीजों में, Accretion Nutraveda ने ₹33.60 करोड़ का ऑपरेशनल रेवेन्यू दर्ज किया, जिस पर ₹5.07 करोड़ का नेट प्रॉफिट (Profit After Tax - PAT) कमाया है। यह नंबर कंपनी के प्रदर्शन को दर्शाता है।
nNatijon ke saath hi, company ke board mein bhi aham pherbadal hue hain. 8 May, 2026 ko do independent directors, Mr. Arun Dash aur Mr. Mahipal Singh Chouhan ne apne pad se istifa de diya. Inki jagah, board ne do naye additional non-executive independent directors - Mr. Chand Rameshbhai Kanabar aur Ms. Grishma A Shewale ki niyukti ko manzoori di hai. Halanki, in niyuktiyon ko shareholder ki manzoori milni baaki hai.
Company ne agle financial year (FY2026-27) ke liye apne audit partners ki bhi ghoshna kar di hai. M/s. Sakhiya & Co. secretarial auditor ke taur par aur M/s. UMT & Co. internal auditor ke taur par phir se niyukt kiye gaye hain.
Haal hi mein Accretion Nutraveda ne apna initial public offering (IPO) poora kiya tha, jisse company ne lagbhag ₹24.77 crore jutaye the. 31 March, 2026 tak, company ke paas ₹655.48 lakh yaani ₹6.55 crore ke unutilized IPO funds maujood hain. Investors ki nazar ab in paison ko kharch karne ki company ki ranneeti aur samay-seema par rahegi.
Yeh company nutraceutical aur health products sector mein kaam karti hai. Health sector ki anya companies mein Panacea Biotec Ltd. aur Ajanta Pharma Ltd. shamil hain.
Ab investor company ke shareholders se naye directors ki manzoori prakriya, baaki bache IPO funds ko istemal karne ki management ki yojnaon aur bhavishya ke vittiya pradarshan par baareeki se nazar rakhenge. Saath hi, naye board sadasyon ka corporate governance aur company ki strategic disha mein kya yogdan rahega, yeh bhi aham hoga.